Bioniche Life Sciences Inc. 25 Years
Contact Us Careers
Home Newsroom
In the News

December 1, 2014
Telesta Therapeutics Announces Key Clinical & Corporate Updates

November 25, 2014
BIONICHE LIFE SCIENCES INC. REBRANDS AS TELESTA THERAPEUTICS INC.

Investors

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.


Newsroom

All Releases

December 2014

01/12/14
Telesta Therapeutics Announces Key Clinical & Corporate Updates

November 2014

25/11/14
BIONICHE LIFE SCIENCES INC. REBRANDS AS TELESTA THERAPEUTICS INC.

13/11/14
Bioniche Life Sciences Inc. Announces Results of Annual General Meeting of Shareholders SHAREHOLDERS

12/11/14
Bioniche Life Sciences Inc. Reports MCNA Update & First Quarter Results

06/11/14
Orphan Drug Designation Update and Annual General Meeting Reminder

October 2014

10/10/14
Bioniche Life Sciences Inc. to Publish Comprehensive Phase 3 Clinical Trial Results In The Journal of Urology

September 2014

29/09/14
Bioniche Life Sciences Inc. Reports Fiscal 2014 Year-End Results

24/09/14
Bioniche Life Sciences Closes Equity Offering

16/09/14
Bioniche Files Final Prospectus For Equity Offering

August 2014

22/08/14
Bioniche Life Sciences Announces Terms of $5 Million Financing & Use of Proceeds

21/08/14
Bioniche Life Sciences Announces Overnight Marketed Offering

19/08/14
Bioniche Announces Q1/2015 Timeline for the Filing of a Biologics License Application for Marketing Approval of MCNA in the United States

July 2014

29/07/14
Bioniche Announces Submission of Orphan Drug Designation Application for MCNA in the United States

18/07/14
Bioniche Announces Intention to File for Marketing Approval of MCNA in the United States

June 2014

13/06/14
Bioniche Life Sciences Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference

03/06/14
Bioniche Provides Corporate Update

May 2014

14/05/14
Bioniche Life Sciences Inc. Reports Fiscal 2014 Third Quarter Results

April 2014

15/04/14
Vétoquinol and Bioniche Life Sciences Inc. Close Sale of Bioniche Animal Health Business

14/04/14
Bioniche Life Sciences Inc. Shareholders Approve Sale of Animal Health Business

03/04/14
ISS Recommends that Bioniche Shareholders Vote in Favour of Animal Health Sale Transaction

03/04/14
Bioniche Life Sciences Inc. Continues to Execute on Strategic Review

March 2014

13/03/14
Bioniche Life Sciences Inc. Holds Shareholder Conference Call/Webcast

04/03/14
Bioniche Life Sciences Inc. Announces Key Corporate Updates

February 2014

26/02/14
Vétoquinol to Acquire the Animal Health Business of Bioniche Life Sciences Inc.

06/02/14
Bioniche Life Sciences Inc. Reports Fiscal 2014 Second Quarter Results and Announces Strategic Expenditure Review and New One Health Strategy

January 2014

07/01/14
Bioniche Life Sciences Inc. Appoints a Chief Operating Officer

December 2013

11/12/13
Bioniche Life Sciences Inc. Delisting Approved by the ASX

04/12/13
Primary and Long-Term Illness Related to E. coli O157 Costs $403.9 Million per Year in Canada

02/12/13
Bioniche Life Sciences Inc. Horse Product Approved for Sale in the U.S.

November 2013

07/11/13
Bioniche Life Sciences Inc. Reports Fiscal 2014 First Quarter Results

04/11/13
Bioniche Life Sciences Inc. Announces the Appointment of a New Chief Executive Officer

October 2013

18/10/13
Bioniche Management Proxy Circular for 2013 Annual and Special Meeting Now Available

07/10/13
Bioniche Provides an Update on Plans for a New Drug Submission Filing in Canada

September 2013

27/09/13
Bioniche Life Sciences Inc. Reports Fiscal 2013 Year-End Results

26/09/13
Bioniche Closes Canadian Equity Offering and Related Private Placement

18/09/13
Bioniche Files Final Prospectus for Canadian Equity Offering

12/09/13
Bioniche Life Sciences Inc. and Concerned Shareholders Announce a Settlement

11/09/13
Bioniche Founder and CEO Announces his New Role with the Company

August 2013

07/08/13
Bioniche Confirms Pricing of Canadian Equity Offering

06/08/13
Bioniche Files Preliminary Prospectus for Canadian Equity Offering

July 2013

23/07/13
Ontario Court Confirms Timing of Bioniche’s Annual Meeting of Shareholders

15/07/13
Bioniche's Lead Animal Health Product Gains Access to Seven Additional European Markets

08/07/13
Health Canada Provides Direction to Bioniche Life Sciences Inc. Regarding New Drug Submission Filing

05/07/13
Paladin Labs Inc. and Bioniche Life Sciences Inc. Officially Close Debt Refinancing and Urocidin™ Licensing Deals

June 2013

28/06/13
Bioniche Responds to Dissident Shareholders' Latest Tactics

27/06/13
Bioniche Life Sciences Inc. to Provide an Update on Vaccine Manufacturing Centre Validation

12/06/13
Bioniche Founder and CEO Addresses Shareholders

05/06/13
Paladin Labs Inc. and Bioniche Life Sciences Inc. Sign Debt Refinancing and Urocidin™ Licensing Deals

May 2013

29/05/13
Bioniche Responds to Dissident Shareholders and Rejects Call for Early Shareholder Meeting

13/05/13
Bioniche Engages Evercore Partners to Assist in the Divestment of its Animal Health Business

08/05/13
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2013 Results

04/05/13
Bioniche Life Sciences Inc. Responds to Dissident Request for Shareholder Meeting

April 2013

26/04/13
Bioniche Life Sciences Inc. Acknowledges Request for Shareholder Meeting

22/04/13
Bioniche Life Sciences Inc. Responds to Letter from Former Biovail Executives

19/04/13
Bioniche Life Sciences Inc. Experiences Increased Trading Activity

18/04/13
Bioniche E. coli O157 Vaccine to be Used in an On-Farm Intervention Study in Sweden

01/04/13
Bioniche Life Sciences Inc. Regains Sponsorship of Urocidin™

March 2013

27/03/13
Bioniche Life Sciences Inc. Receives Government of Canada Support for Second Generation E. coli O157 Vaccine

26/03/13
Bioniche Life Sciences Inc. Reacts to Canadian Federal Budget

07/03/13
Bioniche Life Sciences Inc. Reorganizes One of its Business Units

February 2013

28/02/13
Vaccination of Cattle to Reduce Public Health Risk of E. coli O157 Featured in the Canadian Journal of Public Health

06/02/13
Bioniche Life Sciences Inc. Reports Q2, Fiscal 2013 Results

January 2013

30/01/13
Bioniche Life Sciences Inc. Terminates its License Agreement with Trophogen Inc.

24/01/13
Bioniche Life Sciences Inc. Launches Two New Animal Health Products in Canada

03/01/13
Bioniche Life Sciences Inc. Provides an Update on the Return of Urocidin™ Global Rights

December 2012

21/12/12
Endo Pharmaceuticals Returns Urocidin™ Global Rights to Bioniche Life Sciences Inc.

13/12/12
Bioniche Life Sciences Inc. Achieves Registration of Enhance™ I.A./I.V. in Hong Kong

06/12/12
Bioniche Life Sciences Inc. Announces a Change to its Board of Directors

04/12/12
Bioniche Life Sciences Inc. Launches NexHA™ in Canada

November 2012

21/11/12
U.S. Distributor Appointed for Bioniche’s ImmunocidinTM Canine Oncology Therapy

07/11/12
Bioniche Life Sciences Inc. Reports Q1, Fiscal 2013 Results

05/11/12
Bioniche Life Sciences Inc. Announces Discontinuation of Current Phase III Clinical Trial with Urocidin™

October 2012

17/10/12
Bioniche Life Sciences Inc. Announces North American Market Launch of ImmunocidinTM

September 2012

20/09/12
Bioniche Life Sciences Inc. Discovers a Counterfeit Equine Product

12/09/12
Bioniche Life Sciences Inc. Reports Fiscal 2012 Year-End Results

August 2012

20/08/12
Bioniche Launches New U.S. Equine Product and Acquires Canadian Distribution Rights to Six Additional Products

13/08/12
Bioniche Life Sciences Inc. Enters into an Exclusive U.S. Distribution Agreement for an Equine Product

07/08/12
Special Treatment Certificate Issued for Importation of E. coli O157 Vaccine into the United Kingdom

July 2012

31/07/12
Bioniche Presents Preliminary Data on the Use of In-Licensed Superagonist Hormone Technology in Cattle

30/07/12
Bioniche Life Sciences Inc. Appoints an Independent Chairman of its Board of Directors

23/07/12
Bioniche Life Sciences Inc. Moves Closer to Market Launch of ImmunocidinTM

May 2012

28/05/12
Most Effective Strategy for Managing E. coli O157:H7 in Beef is a Combination of a Pre-Harvest Intervention and Several Processing Interventions

09/05/12
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2012 Results

01/05/12
Bioniche Life Sciences Inc. Commercializing Two Products for Canine Cancer

April 2012

18/04/12
Bioniche Life Sciences Inc. Sponsors Two Major International Livestock Reproduction Conferences

11/04/12
Bioniche Life Sciences Inc. Closes US$20M Financing from Capital Royalty L.P.

March 2012

23/03/12
Bioniche Life Sciences Inc. Enters into a Distribution Agreement for New Animal Health Products in Australia

19/03/12
Bioniche Life Sciences Inc. Accepts US$20M Financing Offer from Capital Royalty L.P.

February 2012

09/02/12
Bioniche Life Sciences Inc. Reports Q2, Fiscal 2012 Results

09/02/12
Bioniche Life Sciences Inc. Q2, Fiscal 2012 Conference Call and Audio Webcast

December 2011

21/12/11
Bioniche Life Sciences Inc. Enters into Two Distribution Agreements for New Animal Health Products

13/12/11
Bioniche E. coli Vaccine Granted Import Access to Australia

12/12/11
Bioniche Life Sciences Inc. Reports Q1, Fiscal 2012 Results

November 2011

15/11/11
Bioniche Life Sciences Inc. Congratulates Dr. Alvaro Morales on his Appointment as Member of the Order of Canada

09/11/11
Bioniche Life Sciences Inc. Holds Annual & Special Meeting of Shareholders

October 2011

27/10/11
Bioniche Life Sciences Inc. Receives Canadian Regulatory Approval for Equine Anti-Inflammatory Product

20/10/11
New York Court Grants Summary Judgment in Favour of Bioniche Life Sciences Inc.

September 2011

29/09/11
Bioniche Life Sciences Inc. Launches Three New Products

22/09/11
Bioniche Life Sciences Inc. Outlines Plan to Achieve Profitability

15/09/11
Bioniche Reports Fiscal 2011 Year-End Results

August 2011

01/08/11
Bioniche Life Sciences Inc. Will Not Proceed With Business and Asset Acquisition of Plasvacc Holdings Limited

July 2011

04/07/11
Bioniche Life Sciences Inc. has Agreed to Acquire Plasvacc Holdings Limited of Australia

June 2011

13/06/11
Bioniche Chief Veterinary Scientific Officer Discusses Vaccine Against E. coli O157 at International Meat Industry Conference

May 2011

17/05/11
Urocidin™ Phase III Clinical Trial Results Presented at AUA Conference in Washington, D.C.

11/05/11
Bioniche Life Sciences Inc. Reports Fiscal 2011 Third Quarter Results

05/05/11
Econiche™ Vaccine Efficacy Challenge Study Summarized in The Canadian Journal of Veterinary Research

April 2011

29/04/11
Animal Health and Food Safety Vaccine Manufacturing Centre Officially Opens in Belleville, Ontario, Canada

March 2011

31/03/11
Folltropin®-V - a Key Bioniche Animal Health Product - Receives Marketing Authorization in China

22/03/11
Bioniche Life Sciences Inc. Keynote Speaker at 7th Annual NZBIO Conference in New Zealand

February 2011

18/02/11
Urocidin™ Phase III Clinical Trial Results To Be Presented At EAU and AUA Conferences

17/02/11
First Patient Enrolled In Second Phase III Clinical Trial Of Urocidin™

15/02/11
Vaccinating Cattle to Protect Human Health a Topic for First International One Health Congress

10/02/11
Bioniche Life Sciences Inc. Reports Fiscal 2011 Second Quarter Results

January 2011

27/01/11
Bioniche Life Sciences Inc. Securities Now Trading on the Australian Securities Exchange (ASX)

20/01/11
Bioniche Life Sciences Inc. Listing on the Australian Securities Exchange (ASX)

04/01/11
Bioniche Completes Australian Offer, Raising A$12.5 Million

03/01/11
Bioniche Announces Reorganization of Leadership Team

December 2010

21/12/10
Bioniche Animal Health and IMV Technologies Sign European Distribution Agreement

16/12/10
Bioniche Closes Canadian Portion of 20 Million Common Share Offer

14/12/10
Canadian Underwriters Exercise Over-Allotment Option as Part of Bioniche Share Offer

13/12/10
Bioniche Files Final Documentation for Canadian Portion of 20 Million Common Share Offer

10/12/10
Bioniche Prices Canadian Portion of 20 Million Common Share Offer

06/12/10
Bioniche, Through Distributor, Provides Exclusive Supply to Angus Association in Australia

November 2010

30/11/10
Bioniche Obtains Exclusive U.S. Rights to Equine Reproductive Product from CreoSalus

22/11/10
Bioniche Files Regulatory Documents for 20 Million Common Share Offer in Canada and Australia

17/11/10
Urocidin Phase III Trial Results Trigger Milestone Payment to Bioniche from Endo

15/11/10
Bioniche Presents at U.S. Animal Health Association Committee on Food & Feed Safety

10/11/10
Bioniche Reports Fiscal 2011 First Quarter Results

October 2010

28/10/10
Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada for a Second Time

19/10/10
Fonds de solidarité FTQ Converting
Remainder of its Preferred Shares in Bioniche

18/10/10
Bioniche Scientists Present at Modern Vaccine & Adjuvant Formulation Conference in France

September 2010

27/09/10
Bioniche Experiences Increased Trading Activity

10/09/10
Bioniche Reports Fiscal 2010 Year-End Results

August 2010

25/08/10
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology

20/08/10
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010

June 2010

23/06/10
Bioniche & Trophogen Sign Exclusive Global Veterinary License Agreement for Superagonist Hormone Technology Platform

17/06/10
Bioniche Strengthens its International Patent Portfolio for its MCC & Oligonucleotide Technology Platforms

02/06/10
Bioniche Animal Health Partners with Bayer Australia to Distribute Livestock Product Line

May 2010

17/05/10
Bioniche Recognizes 10th Anniversary of Walkerton, Ontario Water Contamination Tragedy

12/05/10
Bioniche Reports Fiscal 2010 Third Quarter Results

April 2010

19/04/10
Bioniche Receives FedDev Ontario Investment to Support Fermentation Scale-Up for New Vaccine Manufacturing Centre

March 2010

16/03/10
Canadian Cattle Producers Willing to Make Changes to Prevent E. coli O157 Contamination on their Farms

February 2010

12/02/10
Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights

10/02/10
Bioniche Reports Fiscal 2010 Second Quarter Results

January 2010

29/01/10
Bioniche E. coli O157 Vaccine Recognized in Prestigious Scientific Journal

November 2009

25/11/09
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform

06/11/09
Bioniche Reports Fiscal 2010 First Quarter Results And Achievement of First Milestone Under Licensing Agreement

September 2009

21/09/09
Bioniche Reports Fiscal 2009 Year-End Results

August 2009

24/08/09
Bioniche Phase III Clinical Trial with Urocidin™ Given Continued Green Light by DMC

05/08/09
Bioniche Announces Resignation of its CFO

July 2009

20/07/09
Bioniche Repays Revolving Credit Facility

17/07/09
EconicheTM Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease

10/07/09
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Inc. Sign Licensing Agreement for UrocidinTM

June 2009

22/06/09
Bioniche Provides a Corporate Update

May 2009

28/05/09
Bioniche Represented at House of Commons Sub-Committee on Food Safety

22/05/09
Bioniche Phase III Clinical Trial with Urocidin™ Progressing Well

06/05/09
Bioniche Reports Fiscal 2009 Third Quarter

April 2009

27/04/09
Bioniche Provides a Corporate Update

March 2009

31/03/09
Bioniche Completes Recruitment in First Phase III Clinical Trial with UrocidinTM

13/03/09
EconicheTM Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle

02/03/09
Bioniche Revolving Credit Facility Maturity Date Amended

February 2009

18/02/09
Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology

17/02/09
Bioniche Warrants’ Expiration Date to be Extended

06/02/09
Bioniche Reports Fiscal 2009 Second Quarter

03/02/09
Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable

January 2009

14/01/09
Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada

November 2008

24/11/08
Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile

17/11/08
Update on Bioniche Phase III Clinical Trial in Bladder Cancer

07/11/08
Bioniche Reports Fiscal 2009 First Quarter

October 2008

27/10/08
World’s First Cattle Vaccine to Reduce E. coli O157 Threat Receives Full Licensing Approval in Canada

17/10/08
E. coli O157 Vaccine Efficacy Reinforced by Study Published in Foodborne Pathogens and Disease

September 2008

24/09/08
Canadian Regulator Recognizes Efficacy and Safety of Bioniche E. coli O157 Cattle Vaccine

19/09/08
Bioniche Reports Fiscal 2008 Year-End Results

09/09/08
Bioniche Allows Conversion of Portion of Revolving Credit Facility

August 2008

25/08/08
Bioniche Animal Health Immunotherapy Now Listed as “Organic” for Use in Cattle

18/08/08
Bioniche Phase III Clinical Trial in Bladder Cancer Progressing Well

July 2008

10/07/08
Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary

June 2008

27/06/08
Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference

25/06/08
Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production

17/06/08
Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia.

May 2008

23/05/08
Bioniche Presents Pre-Clinical Research at Two International Conferences

13/05/08
Bioniche Updates re: Mycobacterial Cell Wall Technology Platform

09/05/08
Bioniche Reports Fiscal 2008 Third Quarter

April 2008

21/04/08
Bioniche Appoints U.S. President of Food Safety

18/04/08
Bioniche Reports the Passing of its Board Chair

March 2008

27/03/08
Bioniche Converts a Portion of its Debt to Equity

04/03/08
Bioniche Receives Fast track Designation for First-Line Bladder Cancer Therapy

February 2008

13/02/08
Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin™

12/02/08
Bioniche Reports Fiscal 2008 Second Quarter

08/02/08
Bioniche Receives $5 Million Capital Financing Support to Scale-up E. coli O157:H7 Vaccine Production

05/02/08
USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine

December 2007

21/12/07
Bioniche Amends Terms of Convertible Debt with Laurus Master Funds

20/12/07
Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario

18/12/07
Bioniche Receives $10 Million of Provincial Government Support to Scale-up Vaccine Production in Ontario

17/12/07
Announcement Planned by Ontario Ministry of Economic Development and Trade

04/12/07
Bioniche Recognized as One of the Top 10 Life Science Companies in Canada

November 2007

15/11/07
Bioniche Presents at Annual Convention of Canadian Association of Fairs & Exhibitions

13/11/07
Journal of Food Protection Publishes Two Articles on E. coli O157:H7 Vaccine Efficacy

09/11/07
Bioniche Reports Fiscal 2008 First Quarter

06/11/07
Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference

October 2007

05/10/07
Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine

05/10/07
Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial

04/10/07
Bioniche to Present at BioContact Quebec 2007

September 2007

27/09/07
Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards

26/09/07
Bioniche Reports Fiscal 2007 Year-End Results

24/09/07
Beef Cattle Vaccinated Against E. coli O157:H7

21/09/07
Bioniche Reports Year-End Fiscal 2007 Results

10/09/07
Bioniche Reaches Special Protocol Assessment Agreement with U.S. FDA for Phase III Comparative Bladder Cancer Trial

07/09/07
Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine

06/09/07
Bioniche Responds to Australian Equine Influenza Outbreak

August 2007

24/08/07
Bioniche Ships First Order of E. coli O157:H7 Cattle Vaccine

16/08/07
Bioniche Provides Update on Refractory Bladder Cancer Trial

July 2007

30/07/07
Bioniche Lists Warrants in Connection with March 7, 2007 Offering of Units

19/07/07
Bioniche Appoints New Animal Health and Food Safety Leadership Team

18/07/07
Bioniche Appoints New Director to its Board

June 2007

06/06/07
Solidarity Fund QFL Converting 25% of its Preferred Shares in Bioniche Life Sciences

May 2007

22/05/07
Data Shows Bioniche Proprietary MCC Technology Effective in Inducing Anticancer Activity in 3 Hours

04/05/07
Bioniche Reports Third Quarter Results for Fiscal 2007

01/05/07
Bioniche E. coli O157:H7 Vaccine Discussed at 4th International Conference on Vaccines for Enteric Diseases

April 2007

18/04/07
Bioniche Eliminates Convertible Debt with Laurus Master Funds

16/04/07
Bioniche Presents Additional Data on the Anticancer Activity of MCC Against Peritoneal Carcinomatosis

03/04/07
Non-Antibiotic Treatment for Equine Endometritis Study Data Published in International Peer-Reviewed Journal

March 2007

30/03/07
Bioniche Recognized with Québec Biotechnology Award

29/03/07
Bioniche and Technology Partnerships Canada Amend Agreement on MCC Research Project

13/03/07
Bioniche Closes C$17.5 Million Equity Financing

02/03/07
Bioniche Files Final Short-Form Prospectus for Offering of Units

February 2007

09/02/07
Bioniche Files Preliminary Short-Form Prospectus for Offering of Units

02/02/07
Bioniche Reports Second Quarter Results for Fiscal 2007

January 2007

12/01/07
Bioniche Further Pays Down Debt with Laurus Master Funds

10/01/07
Canadian Research Collaboration Produces World's First Food Safety Vaccine: Against E. coli 0157:H7

December 2006

22/12/06
Bioniche E. coli O157:H7 Cattle Vaccine Authorized for Field Use in Canada

22/12/06
Bioniche Further Pays Down Debt

15/12/06
Bioniche Life Sciences Experiences Significant Trading Volume Following Progress Update on E. coli O157:H7 Cattle Vaccine Canadian Regulatory Status

08/12/06
Bioniche Life Sciences Clears Path for Priority Review of its E. coli O157:H7 Cattle Vaccine in Canada

08/12/06
Bioniche Completes Sale of Two Remaining Assets Associated with Irish Pharma Group

06/12/06
Bioniche Life Sciences' E. coli O157:H7 Cattle Vaccine Data Presented at Two International Symposia

November 2006

10/11/06
Bioniche Reports First Quarter Results for Fiscal 2007

08/11/06
First Patient Treated in Bioniche Phase III Refractory Bladder Cancer Trial

07/11/06
Bioniche Plans to Liquidate Two Remaining Assets Associated with Irish Pharma Group

02/11/06
Bioniche Expands Patent Portfolio with Three New Patents

October 2006

31/10/06
Bioniche to Present at Rodman & Renshaw 8th Annual Healthcare Conference

02/10/06
Bioniche Board Approves a Shareholders Rights Plan

September 2006

29/09/06
Bioniche Life Sciences Inc. Re-Files its 2005 MD&A and Certificates

28/09/06
Bioniche Reports Fiscal Year-End Results

22/09/06
Update for Bioniche Year-End Fiscal 2006 Call/Cast Per CNW Group

15/09/06
New Date for Bioniche Year-End Fiscal 2006 Call/Cast

11/09/06
Bioniche Reports Year-End Fiscal 2006 Results

June 2006

29/06/06
Bioniche Presents Additional Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Human Bladder Cancer Cells

27/06/06
Cameron Groome Joins Bioniche as Executive Vice-President, Corporate & Strategic Development

05/06/06
Counterfeit Product Linked to Death of Ontario Horse

May 2006

24/05/06
Mycobacterial Cell Wall-DNA Complex (MCC) Demonstrates Anticancer Activity in an Animal Model of Colon Cancer

23/05/06
Bioniche Closes Sale of its Proprietary Cystitis Product

09/05/06
Bioniche Third Quarter Results Correction

05/05/06
Bioniche Reports Third Quarter Results for Fiscal 2006

04/05/06
U.S. FDA Grants Fast Track Designation for Bioniche Bladder Cancer Product

03/05/06
Bioniche Sells Proprietary Cystitis Product for $10 Million Cdn.

02/05/06
Media Advisory - Bioniche Reports Third Quarter Results for Fiscal 2006

April 2006

03/04/06
Bioniche Receives FDA Approval to Proceed with Phase III Bladder Cancer Trials

March 2006

27/03/06
Bioniche to Host Bladder Cancer Roundtable

22/03/06
Updates on MCC Phase III Bladder Cancer Study and E. coli O157:H7 Cattle Vaccine Regulatory Progress

13/03/06
Bioniche Granted First Major Composition Patent for Oligonucleotide Technology

February 2006

08/02/06
Bioniche Reports Second Quarter Results for Fiscal 2006

07/02/06
U.S. FDA Accepts Part One of Bioniche Program for Phase III Clinical Trials with MCC for Bladder Cancer

02/02/06
Media Advisory - Bioniche Reports Second Quarter Results for Fiscal 2006

01/02/06
Bioniche and RoundTable Healthcare Partners Close Sale of Bioniche Pharma Group Ltd.

January 2006

12/01/06
Bioniche Signs Definitive Purchase Agreement for Sale of Pharma Group to RoundTable Healthcare Partners

December 2005

09/12/05
Bioniche Completes Private Financing

November 2005

04/11/05
Bioniche Reports First Quarter Results for Fiscal 2006

01/11/05
Bioniche Annual Meeting Web Cast and First Quarter Results for Fiscal 2006

October 2005

28/10/05
Bioniche Clarifies Terms of Pharma Group Sale and Private Placement

18/10/05
Bioniche Pharma Group and AngioDynamics Sign Exclusive Distribution Agreement for Sotradecol(R) Injection

14/10/05
Bioniche Discussing Potential Private Placement

05/10/05
Bioniche and ICC Private Equity Fund Agree to Sell Bioniche Pharma Group to RoundTable Healthcare Partners

04/10/05
Bioniche Retains Blackmont Capital to Assist in the Sale of its Pharma Business Unit

September 2005

29/09/05
Bioniche Reports Fiscal Year-End Results and Unveils Plans to Convert Business Unit into Cash

26/09/05
Bioniche in Good Standing with Technology Partnerships Canada (TPC)

20/09/05
New Date/Time for Bioniche Fiscal 2005 Year-End Call/Cast

15/09/05
Bioniche Reports Year-End Fiscal 2005 Results

July 2005

14/07/05
Bioniche Launches Sotradecol® Injection for Varicose Veins in U.S. Market

12/07/05
Bioniche Reports Positive News from BetacTM Product Recall Investigation

June 2005

20/06/05
Bioniche Life Sciences Retains GCI Group as Strategic Investor Relations Counsel

17/06/05
Bioniche Issues Recall of BetacTM

16/06/05
Bioniche Presents Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Peritoneal (Colon) Cancer

13/06/05
Bioniche Appoints New Chief Medical Officer to Advance Clinical Trials

03/06/05
New Studies Demonstrate Immunomodulatory Activity of Bioniche Technology in Dogs

03/06/05
New Studies Demonstrate Immunomodulatory Activity of Bioniche Technology in Dogs

01/06/05
Bioniche Pharma Group and Grünenthal Sign Exclusive Agreement for Distribution of Suplasyn®

May 2005

26/05/05
Bioniche Granted European Patent for Mycobacterial Cell Wall-DNA Complex (MCC) as Prostate Cancer Treatment

24/05/05
Bioniche Mycobacterial Cell Wall Extract (MCWE) Granted New Patent for Production Performance in Animals

17/05/05
Bioniche Granted Additional Patent for Mycobacterial Cell Wall Technology

13/05/05
Bioniche Announces Change in Board of Directors Composition

09/05/05
Bioniche Reports Third Quarter Fiscal 2005 Results

04/05/05
Bioniche to Present at Rodman & Renshaw

03/05/05
Bioniche Reports Third Quarter Results for Fiscal 2005

April 2005

18/04/05
Bioniche Presents Data on Prevention and Management of Urinary Tract Infections Using Cystistat®

March 2005

29/03/05
Bioniche Granted European Patent for MCC in Bladder Cancer

22/03/05
Bioniche Presents Further Data on Mycobacterial Cell Wall-DNA Complex (MCC) at European Association of Urology 20th Congress

14/03/05
Further Research Studies Support E. coli Cattle Vaccine Efficacy

07/03/05
Research Shows Promise for Easy, Effective Management of Sow Breeding

February 2005

10/02/05
Bioniche Reports Second Quarter Fiscal 2005 Results

09/02/05
Bioniche Reports Second Quarter Results for Fiscal 2005

January 2005

28/01/05
Bioniche to Submit Additional Safety Data for its E. coli Vaccine

21/01/05
Bioniche Receives Authorization to Market Folltropin®-V in Additional EU Countries

December 2004

23/12/04
Bioniche Animal Health Appoints New Leaders of European and Australian/Asian Operations

06/12/04
Senior Personnel Change at Bioniche

03/12/04
Livestock Revolution in Global Agriculture

November 2004

29/11/04
New Treatment for Equine Endometritis Given USDA Approval

22/11/04
FDA Approves Bioniche Pharma ANDA for Sotradecol Injection for the Treatment of Varicose Veins

18/11/04
New Data Confirms Unique Anticancer Activity Profile

09/11/04
Bioniche Discusses Further Details of the Phase III Clinical Trial with Urocidin for the Treatment of Bladder Cancer

09/11/04
Bioniche Revenues Increase in First Quarter of Fiscal 2005

08/11/04
New Studies Demonstrate Anti-Cancer Activity of Bioniche Technology Against Canine Cancer

04/11/04
Bioniche Reports First Quarter Results for Fiscal 2005

October 2004

28/10/04
Investment in Bioniche Life Sciences Inc.The Solidarity Fund QFL will invest $10 M and the Bio-Food Investment Fund $2 Mac

20/10/04
Bioniche Annual Report Correction

15/10/04
Industrial Research Chairs in Food Safety Filled

06/10/04
Bioniche Expands its Intellectual Property Portfolio

September 2004

23/09/04
Bioniche Presents Data on Cystistat and Launches Product Web Site at Inaugural Multinational Interstitial Cystitis Association Annual Meeting

21/09/04
Bioniche Reports Year-End Fiscal 2004 Results

20/09/04
Bioniche Appoints a Chief Operating Officer

15/09/04
Bioniche Reports Year-End Fiscal 2004 Results

August 2004

26/08/04
Bioniche Ranked Among the Top 100 Global Biotechnology Companies by Med Ad News

06/08/04
Mycobacterial Cell Wall Formulation Shows Promise in Treating Equine Endometritis

03/08/04
Bomac Laboratories Ltd. to Distribute Bioniche Cue-Mate® Technology in New Zealand

July 2004

22/07/04
Bioniche Presents Pre-Clinical Data on Anti-Cancer Agents and Immunomodulatory Molecules at International Congress of Immunology

June 2004

21/06/04
Bioniche Commences Sales of Cue-Mate® Animal Reproductive Technology in Australian Cattle Market

18/06/04
Bioniche Receives Approval For New Animal Health Product Indication

14/06/04
Pharmacoeconomic Study into Use of Suplasyn® Demonstrates Reduced Pain and Cost-Effectiveness in Treatment of Patients with Osteoarthritis of the Knee

14/06/04
Bioniche Serves Community Needs Through New Pet Loss Program

10/06/04
Bioniche Presents Positive Data on Anti-Cancer Activity of MCC at 22nd Annual Meeting of American College of Veterinary Internal Medicine

08/06/04
Bioniche Ranked Among Canada’s Top 100 Fastest-Growing Companies by PROFIT Magazine

01/06/04
Bioniche Retains The Anne McBride Company Inc.

May 2004

21/05/04
Bioniche’s Pharmaceutical Business Unit Raises 10.8 Million Euro for Expansion of Manufacturing Facilities

20/05/04
Bioniche Presents Bladder Cancer Clinical Trial and Research Data to American Urological Association Annual Meeting

14/05/04
Bioniche Reports Third Quarter Fiscal 2004 Results

12/05/04
Bioniche Reports Third Quarter Fiscal 2004 Results Web Cast

12/05/04
Bioniche E. coli 0157 Vaccine Shows Further Promise

April 2004

19/04/04
Bioniche Acquires Cue-Mate® Reproductive Technology From Pfizer

March 2004

29/03/04
Bioniche Announces Results of Phase I Prostate Cancer Study

February 2004

17/02/04
Bioniche Life Sciences Completes $10,000,000 Financing

13/02/04
Bioniche Reports Second Quarter 2004 Financial Results

05/02/04
Bioniche Enters Into Agreement For $10,000,000 Financing

January 2004

10/01/04
Bioniche Life Sciences and AB Technology Sign Purchase Agreement


Newsroom

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Human Health
One Health

Copyright 2004, Bioniche Life Sciences Inc. All rights reserved  |  Legal Disclaimer  |  Privacy Policy